Other formats:
BibTeX
LaTeX
RIS
@inproceedings{721579,
author = {Kuglík, Petr and Zaoralová, Romana and Filková, Hana and Grešliková, Henrieta and Němec, Pavel and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Krejčí, M. and Hájek, Roman},
address = {Netherlands},
booktitle = {Chromosome Research},
keywords = {Multiple myeloma; cIg-FISH; 13q deletion; p53 deletion; t(4;14); amp1q21; Velcade; Thalidomide},
language = {eng},
location = {Netherlands},
pages = {185-186},
publisher = {Springer},
title = {Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)},
year = {2007}
}
TY - JOUR
ID - 721579
AU - Kuglík, Petr - Zaoralová, Romana - Filková, Hana - Grešliková, Henrieta - Němec, Pavel - Oltová, Alexandra - Pour, Luděk - Adam, Zdeněk - Krejčí, M. - Hájek, Roman
PY - 2007
TI - Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
PB - Springer
CY - Netherlands
KW - Multiple myeloma
KW - cIg-FISH
KW - 13q deletion
KW - p53 deletion
KW - t(4;14)
KW - amp1q21
KW - Velcade
KW - Thalidomide
N2 - The aim of this study was to investigate if Thalidomide or Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers in patients with relapsed multiple myeloma (MM). We have focused on four chromosomal aberrations known as negative prognostic factors in MM treated by conventional or myeloablative treatment: deletion of 13q14, deletion of 17p13 (p53), translocation t(4;14) and amplification of CKS1B gene (amp1q21). We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Two groups of patients with relapsed multiple myeloma of similar age, sex, stage of the disease and other parameters were treated by Thalidomide based regimens (24 patients) and by Bortezomib based regimens (18 patients). In our preliminary experiments, we did not find statistically significant difference in OS and TTP between patients with/without chromosomal aberrations (del p53, t(4;14), ampl 1q21). So it is possible that the new drugs overcome their negative prognostic impact. Patients with 13q14 deletion had significant shorter time to progression median (8.9 month) in comparison with patients lacking RB deletion. Similarly, patients with combination of 3 or 4 of unfavorable cytogenetic abnormalities had significant shorter time to progression median (6.0 month) in comparison with patients with 1 or 2 aberrations These data suggest that cytogenetic abnomalities can define subgroup of patients with relapsed MM not benefiting from Thalidomide and velcade treatment. Data are still preliminary and we need wait for results from large randomized trials.
ER -
KUGLÍK, Petr, Romana ZAORALOVÁ, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, M. KREJČÍ and Roman HÁJEK. Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade). In \textit{Chromosome Research}. Netherlands: Springer, 2007, p.~185-186. ISSN~0967-3849.
|
